Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05025800 · ClinicalTrials.gov registry record · Phase 1

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

A Phase 1 study of Indolent B-Cell Non-Hodgkin Lymphoma and Ann Arbor Stage III Grade 2 Follicular Lymphoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
47
Enrollment target
1
Study location

NCT05025800 is a Phase 1 study of Indolent B-Cell Non-Hodgkin Lymphoma and Ann Arbor Stage III Grade 2 Follicular Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 47 participants, below the 64-participant average among 6 other Indolent B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05025800, a Phase 1 study of Indolent B-Cell Non-Hodgkin Lymphoma and Ann Arbor Stage III Grade 2 Follicular Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
47 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that binds to a protein called CD20 found on B-cells, and may kill cancer cells. Giving ALX148 in combination with rituximab and lenalidomide may help to control the disease.

Conditions Studied

Indolent B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage III Grade 2 Follicular Lymphoma Ann Arbor Stage III Grade 3 Follicular Lymphoma Ann Arbor Stage IV Grade 1 Follicular Lymphoma Ann Arbor Stage III Marginal Zone Lymphoma Ann Arbor Stage IV Marginal Zone Lymphoma Aggressive B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage IV Grade 2 Follicular Lymphoma Ann Arbor Stage IV Grade 3 Follicular Lymphoma Composite Lymphoma

Interventions

  • DRUG Lenalidomide
  • BIOLOGICAL Rituximab
  • DRUG CD47 Antagonist ALX148

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2021-10-13
Est. Completion 2028-03-21
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05025800

The ClinicalTrials.gov registry entry for NCT05025800 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 6 other Indolent B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (27% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Indolent B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.

NCT05025800 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05025800 about?

NCT05025800 is a clinical study titled "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma". This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with ALX148, may induce changes in body's immune system and may i...

What is the current status of trial NCT05025800?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2021-10-13. Estimated completion is 2028-03-21.

What conditions does trial NCT05025800 study?

This clinical trial studies the following conditions: Indolent B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma.

What interventions are being tested in trial NCT05025800?

The interventions under investigation include: Lenalidomide (DRUG), Rituximab (BIOLOGICAL), CD47 Antagonist ALX148 (DRUG).

Who is sponsoring clinical trial NCT05025800?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05025800 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Indolent B-Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Indolent B-Cell Non-Hodgkin Lymphoma

All registered trials for this condition

Ann Arbor Stage III Grade 2 Follicular Lymphoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.